Platelet Reactivity in Depressed Patients Treated With Paroxetine

27 subjects: 15 patients with DSM-IV major depression (mean age 37 +/- 7 years, 10 with ≥1 traditional IHD risk factor) and 12 normal comparison subjects (mean age 36 +/- 7 years). None of the subjects had evidence of ischemic heart disease.

Paroxetine 20 mg/d oral open-label for 6 weeks (administered to the depressed patients)

Pre-treatment baseline (for intervention effect) and healthy controls (for baseline comparison)

In vivo platelet activation, secretion, and dose-response aggregation (measured by platelet binding of monoclonal antibodies anti-ligand-induced binding site and GA6, and plasma concentrations of platelet factor 4) under basal conditions and after a mild exercise challengesurrogate